… , including patient selection and therapeutic interventions. Herein we report on 171 patients
with CML with an inadequate response to imatinib assessed for BCR-ABL kinase domain …

… in a proportion of patients receiving imatinib monotherapy, mainly in patients with advanced-…
300 consecutive patients suffering from all stages of Philadelphia (Ph) and/or BCR-ABL–…

… patient's past tolerability issues to imatinib, or comorbid conditions. Here, we propose a
treatment … for imatinib-resistant patients based on BCR-ABL mutation status and patient history. …

… in association with clinical resistance to imatinib. We identified a group of … type Bcr-Abl and
below or just above steady state trough plasma concentrations in patients on 400 mg imatinib …

… CML patients with stable undetectable level of BCR-ABL transcripts. Our findings from 509
patients suggest that imatinib … and risk of death, with all CML patients alive at 2-year follow-up. …

… of nine patients that were resistant to treatment with imatinib 11 … BCR-ABL to identify novel
imatinib-resistant BCR-ABL point … previously identified in patients with imatinib resistance. …

… -risk patients at … BCR-ABL1 from the individual patient baseline (pre-imatinib) value when
measured at 3 months was strongly associated with significant differences in outcome. Patients …

… The aim of this study was to identify ABL point mutations and/or amplification in patients
who failed or lost response to imatinib in order to determine the association with clinical …

… of patients with chronic myeloid leukemia. We determined whether BCR-ABL continues
to decline with longer imatinib … and the incidence and consequence of undetectable BCR-ABL. …

… structure of imatinib, binds to BCRABL with a higher affinity than imatinib because … imatinib
at inhibiting unmutated BCR-ABL in vitro.Dasatinib was developed independently of imatinib …